Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This Comment article argues that we should more comprehensively study the biology of benign tumours, as this might provide crucial insights into our understanding of cancer biology and metastasis.
The incidence of cancer in the small intestine is considerably lower than the incidence of cancer in the large intestine. Why might this be? This article suggests that the microbiota might be part of the explanation for this difference.
Metaplastic breast carcinoma (MBC) accounts for 0.2–5% of invasive breast cancers. The majority of MBCs have a triple-negative phenotype, are highly heterogeneous and respond poorly to chemotherapy. Understanding their divergent differentiation and identifying the cell of origin might provide some much-needed insight into this disease.
NUT midline carcinoma, a squamous cell carcinoma, is one of the most aggressive human cancers, and there is a desperate need for effective therapies for patients with this disease.
Stage MS neuroblastoma is unique in that it regresses without treatment. Could a better understanding of the biology of these tumours inform how high-risk neuroblastoma and other paediatric malignancies are treated?